Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKrit Jaikumkaoen_US
dc.contributor.authorAnchalee Pongchaidechaen_US
dc.contributor.authorNuttawud Chueakulaen_US
dc.contributor.authorLa ongdao Thongnaken_US
dc.contributor.authorKeerati Wanchaien_US
dc.contributor.authorVaranuj Chatsudthipongen_US
dc.contributor.authorNipon Chattipakornen_US
dc.contributor.authorAnusorn Lungkaphinen_US
dc.description.abstract© 2018 John Wiley & Sons Ltd. Aim: To evaluate the renoprotective roles of dapagliflozin in prediabetic rats in order to elucidate the effects of this sodium-glucose co-transporter-2 (SGLT2) inhibitor on the renal complications associated with metabolic dysfunction in diet-induced obesity. Methods: Obesity was induced by feeding a high-fat diet (HFD) to male Wistar rats for 16weeks. HFD-fed rats were treated with dapagliflozin (1 mg/kg/d) or metformin (30mg/kg/d) by oral gavage for 4weeks after insulin resistance had been established. The metabolic characteristics and renal function associated with lipid accumulation, inflammation, fibrosis, endoplasmic reticulum (ER) stress and apoptosis in the renal tissue were examined. Results: The results showed that HFD-fed rats developed both obesity and impaired renal function, along with increased renal triglyceride accumulation. Importantly, dapagliflozin had greater efficacy in improving renal function and reducing both body weight and visceral fat accumulation than metformin treatment. Dapagliflozin and metformin were found to have similar effects regarding the suppression of renal triglycerides, superoxide dismutase (SOD) expression and malondialdehyde (MDA) levels, subsequently leading to a decrease in renal inflammation and fibrosis. Renal ER stress and apoptosis were increased in HFD-fed rats and were effectively reduced after administration of dapagliflozin. The expression of renal SGLT2 was not affected by administration of dapagliflozin or metformin. Conclusion: Collectively, these findings indicate that dapagliflozin exerts renoprotective effects by alleviating obesity-induced renal inflammation, fibrosis, ER stress, apoptosis and lipid accumulation in the prediabetic condition.en_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.titleDapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic ratsen_US
article.title.sourcetitleDiabetes, Obesity and Metabolismen_US of Medicine, Chiang Mai Universityen_US Fah Luang Universityen_US Universityen_US Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.